- Home
- CCIA vs CINGW Comparison
CCIA vs CINGW Comparison
Compare CCIA & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIA
- CINGW
- Stock Information
- Founded
- CCIA N/A
- CINGW N/A
- Country
- CCIA
- CINGW United States
- Employees
- CCIA N/A
- CINGW 13
- Industry
- CCIA
- CINGW Biotechnology: Pharmaceutical Preparations
- Sector
- CCIA
- CINGW Health Care
- Exchange
- CCIA Nasdaq
- CINGW Nasdaq
- Market Cap
- CCIA N/A
- CINGW N/A
- IPO Year
- CCIA 2023
- CINGW 2021
- Fundamental
- Price
- CCIA $25.74
- CINGW $0.06
- Analyst Decision
- CCIA
- CINGW
- Analyst Count
- CCIA 0
- CINGW 0
- Target Price
- CCIA N/A
- CINGW N/A
- AVG Volume (30 Days)
- CCIA N/A
- CINGW N/A
- Earning Date
- CCIA N/A
- CINGW N/A
- Dividend Yield
- CCIA N/A
- CINGW N/A
- EPS Growth
- CCIA N/A
- CINGW N/A
- EPS
- CCIA N/A
- CINGW N/A
- Revenue
- CCIA N/A
- CINGW N/A
- Revenue This Year
- CCIA N/A
- CINGW N/A
- Revenue Next Year
- CCIA N/A
- CINGW N/A
- P/E Ratio
- CCIA N/A
- CINGW N/A
- Revenue Growth
- CCIA N/A
- CINGW N/A
- 52 Week Low
- CCIA N/A
- CINGW N/A
- 52 Week High
- CCIA N/A
- CINGW N/A
- Technical
- Relative Strength Index (RSI)
- CCIA 43.59
- CINGW N/A
- Support Level
- CCIA $25.63
- CINGW N/A
- Resistance Level
- CCIA $25.85
- CINGW N/A
- Average True Range (ATR)
- CCIA 0.13
- CINGW 0.00
- MACD
- CCIA -0.01
- CINGW 0.00
- Stochastic Oscillator
- CCIA 30.11
- CINGW 0.00
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About CINGW Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.